Investigators enrolled 203 adults attending hypertension and diabetes clinics at Cape Coast Teaching Hospital. The cohort was female-predominant and skewed toward older age groups; most participants had both diabetes and hypertension and reported long disease durations. The study team observed that more than 80% of participants had at least two cardiometabolic conditions, while over two-thirds met the harmonised criteria for metabolic syndrome. Overweight and obesity affected in excess of 80% of participants. The authors operationally defined cardiometabolic multimorbidity as presence of two or more of hypertension, type 2 diabetes, MetS, or chronic kidney disease (CKD), acknowledging conceptual overlap because MetS incorporates blood pressure and glycaemic components.
Approximately nine in ten participants were receiving antihypertensive therapy, and more than 90% were on glucose-lowering medications. Treatment rates were therefore high. The cohort nevertheless showed substantial residual uncontrolled blood pressure and hyperglycaemia despite treatment. The study team reported that glucose-lowering medication use correlated with improved glycaemic control (reported OR: 7.16, 95% CI: 3.31–15.47, p < 0.001). Antihypertensive treatment was associated with lower odds of uncontrolled blood pressure (adjusted OR: 0.25, 95% CI: 0.07–0.90, p = 0.033). The authors used American Diabetes Association glycaemic targets in secondary analyses and WHO STEPwise procedures for blood pressure and anthropometry.
Multivariable logistic regression identified obesity as the strongest independent predictor of CKD in this sample. The investigators reported markedly elevated adjusted odds for CKD among participants classified as obese (Obese I/II categories), with effect sizes described in the results. Waist circumference, BMI and visceral adiposity measurements were collected according to WHO STEPwise methods, and renal function was estimated using serum creatinine-based eGFR via the 2021 CKD-EPI equation. The authors noted that persistence of reduced eGFR for ≥3 months and albuminuria were not established in this cross-sectional assessment, a limitation that affects CKD staging.
The study genotyped selected candidate variants implicated in glucose and blood pressure regulation, adiposity and renal disease. These included TCF7L2 rs7903146, AGT, ACE, LEPR, ADRB3, KCNJ11, PPARG, and APOL1 risk variants. Among these, the TCF7L2 rs7903146 CT genotype associated with higher odds of hypertension (adjusted OR reported by the authors). Most other candidate variants, including the APOL1 risk alleles, did not show consistent associations with the outcomes measured in this cohort. The authors emphasised that the genetic findings are exploratory, that p-values are nominal (no multiple-comparison correction was applied), and that replication in larger, community-based samples is required.
Receiver operating characteristic analyses compared three model classes: clinical/lifestyle-only, genetic-only, and combined clinical/lifestyle plus genetic models. In-sample discrimination was highest for combined models, with reported AUCs between 0.83 and 0.89. Clinical and lifestyle models alone produced AUCs in the 0.76–0.83 range, while genetic-only models performed least well (AUCs 0.63–0.67). The authors cautioned that these AUCs represent apparent discrimination because models were developed and evaluated on the same dataset without internal or external validation.
The authors listed multiple limitations inherent to the design and setting. This was a hospital-based, cross-sectional sample of 203 participants, limiting generalisability to community settings. CKD classification relied on a single eGFR measurement without confirmation of chronicity or routine albuminuria assessment. Genetic analyses were candidate-driven, exploratory, and underpowered for small effect sizes; the authors did not apply formal correction for multiple comparisons and recommend cautious interpretation. The report calls for replication of genetic signals in larger, community-based cohorts and suggests integrated risk-factor management focused on obesity and treatment optimisation as immediate clinical priorities, while leaving open specific trial design or regulatory milestones for subsequent research.